文献速递冠心病血脂与心血管预防

无创斑块成像加速冠心病药物研发

Noninvasive Plaque Imaging to Accelerate Coronary Artery Disease Drug Development.
PubMed 文献 · Circulation · 2022-11-28

综述指出无创冠脉成像(CT、PET、CMR)可识别不同预后意义的冠脉粥样硬化表型,通过富集高风险表型或作为2期试验主要终点加速药物研发,并呼吁全球共识与监管合作。

要点

  • 无创冠脉成像可定量评估斑块表型,不同表型对应不同缺血事件风险。
  • 高风险表型富集或作为2期主要终点可加速冠心病药物研发。
  • 他汀等药物对斑块进展和稳定化的获益与临床终点相关。

核心结论

  • 无创冠脉成像技术有潜力通过富集高风险表型或作为2期主要终点加速冠心病药物研发。

研究设计与样本

  • 综述总结了当前可用的无创冠脉成像技术及其在临床试验中的应用,包括对样本量需求的影响和潜在局限性。

主要发现

  • 冠脉斑块表型从高风险富脂薄纤维帽粥样瘤到低风险静止偏心非阻塞钙化斑块存在显著差异,反映不同病理生理通路和急性缺血事件风险。
  • 无创冠脉成像技术包括计算机断层扫描、正电子发射断层扫描和冠脉磁共振成像。
  • FDA已批准120种情况的替代终点,但未批准冠心病替代终点。
  • 有稳健数据显示他汀等药物对冠脉病变进展和斑块稳定化的有益效应与死亡率和主要不良心血管事件等临床终点相关。

临床怎么用

  • 可考虑将无创冠脉成像用于2期试验,通过富集高风险表型或作为药物疗效主要终点加速研发。
  • 需就成像终点和协议达成全球共识,并与监管机构合作构建可持续的分阶段路径。

局限性

  • 综述讨论了当前无创冠脉成像技术的潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery disease (CAD) remains the leading cause of adult mortality globally. Targeting known modifiable risk factors has had substantial benefit, but there remains a need for new approaches. Improvements in invasive and noninvasive imaging techniques have enabled an increasing recognition of distinct quantitative phenotypes of coronary atherosclerosis that are prognostically relevant. There are marked differences in plaque phenotype, from the high-risk, lipid-rich, thin-capped atheroma to the low-risk, quiescent, eccentric, nonobstructive calcified plaque. Such distinct phenotypes reflect different pathophysiologic pathways and are associated with different risks for acute ischemic events. Noninvasive coronary imaging techniques, such as computed tomography, positron emission tomography, and coronary magnetic resonance imaging, have major potential to accelerate cardiovascular drug development, which has been affected by the high costs and protracted timelines of cardiovascular outcome trials. This may be achieved through enrichment of high-risk phenotypes with higher event rates or as primary end points of drug efficacy, at least in phase 2 trials, in a manner historically performed through intravascular coronary imaging studies. Herein, we provide a comprehensive review of the current technology available and its application in clinical trials, including implications for sample size requirements, as well as potential limitations. In its effort to accelerate drug development, the US Food and Drug Administration has approved surrogate end points for 120 conditions, but not for CAD. There are robust data showing the beneficial effects of drugs, including statins, on CAD progression and plaque stabilization in a manner that correlates with established clinical end points of mortality and major adverse cardiovascular events. This, together with a clear mechanistic rationale for using imaging as a surrogate CAD end point, makes it timely for CAD imaging end points to be considered. We discuss the importance of global consensus on these imaging end points and protocols and partnership with regulatory bodies to build a more informed, sustainable staged pathway for novel therapies.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Figtree GA, Adamson PD, Antoniades C, et al. Noninvasive Plaque Imaging to Accelerate Coronary Artery Disease Drug Development. Circulation. 2022. PMID: 36441819. doi:10.1161/CIRCULATIONAHA.122.060308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。